Tricuspid valve transcatheter edge-to-edge repair in patients with cardiac implantable electronic devices: insights from EuroTR
Background - Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is increasingly used in patients with severe tricuspid regurgitation (TR) at high surgical risk. Long-term outcomes in those with transvalvular cardiac implantable electronic devices (CIEDs) remain insufficiently characterized....
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
8 December 2025
|
| In: |
JACC Cardiovascular interventions
Year: 2025, Jahrgang: 18, Heft: 23, Pages: 2878-2891 |
| ISSN: | 1876-7605 |
| DOI: | 10.1016/j.jcin.2025.09.033 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1016/j.jcin.2025.09.033 Verlag, kostenfrei, Volltext: https://www.sciencedirect.com/science/article/pii/S1936879825024859 
|
| Verfasserangaben: | Jennifer von Stein, MD, Philipp von Stein, MD, Roman Pfister, MD, Karl-Patrik Kresoja, MD, Vera Fortmeier, MD, Benedikt Koell, MD, Wolfgang Rottbauer, MD, Mohammad Kassar, MD, Bjoern Goebel, MD, Paolo Denti, MD, Paul Achouh, MD, Tienush Rassaf, MD, Manuel Barreiro-Perez, MD, Peter Boekstegers, MD, Andreas Rück, MD, Monika Zdanyte, MD, Marianna Adamo, MD, Flavien Vincent, MD, PHD, Philipp Schlegel, MD, Sebastian Rosch, MD, Mirjam G. Wild, MD, Christian Besler, MD, Stefan Toggweiler, MD, Stephanie Brunner, MD, Julia Grapsa, MD, Tiffany Patterson, MD, Holger Thiele, MD, Tobias Kister, MD, Giuseppe Tarantini, MD, PHD, Giulia Masiero, MD, Marco De Carlo, MD, Alessandro Sticchi, MD, Fabian Voss, MD, Amin Polzin, MD, Antonio P. Rubbio, MD, Francesco Bedogni, MD, Thorald Stolte, MD, Thomas Nestelberger, MD, Tomás Benito González, MD, Mathias H. Konstandin, MD, Eric Van Belle, MD, PHD, Marco Metra, MD, Tobias Geisler, MD, Rodrigo Estévez-Loureiro, MD, Amir A. Mahabadi, MD, Nicole Karam, MD, Francesco Maisano, MD, Philipp Lauten, MD, Fabien Praz, MD, Mirjam Kessler, MD, Daniel Kalbacher, MD, Volker Rudolph, MD, Philipp Lurz, MD, Juan F. Granada, MD, Jörg Hausleiter, MD, Lukas Stolz, MD, Christos Iliadis, MD, the EuroTR Investigators |
| Zusammenfassung: | Background - Tricuspid valve transcatheter edge-to-edge repair (T-TEER) is increasingly used in patients with severe tricuspid regurgitation (TR) at high surgical risk. Long-term outcomes in those with transvalvular cardiac implantable electronic devices (CIEDs) remain insufficiently characterized. - Objectives - The aim of this study was to evaluate procedural and clinical outcomes of T-TEER in patients with CIED leads in a real-world cohort. - Methods - Among 3,025 patients undergoing T-TEER at 26 centers (2016-2024), 851 (28.1%) had transvalvular CIED leads. Residual TR at discharge and follow-up and the composite of all-cause mortality or heart failure hospitalization at 2 years were assessed. CIED function was evaluated preprocedure and postprocedure. Propensity score matching (1:1) was conducted to compare outcomes between patients with and those without CIEDs. - Results - CIED function remained stable, and no lead revision was required. At discharge, TR ≤1+ and ≤2+ was achieved in 39.9% and 79.8%, respectively; at follow-up (median 269 days; Q1-Q3: 63-423 days), TR ≤1+ and ≤2+ persisted in 29.3% and 69.1%. In 385 matched pairs, residual TR, functional status, and 2-year heart failure hospitalization-free survival were comparable between patients with and those without CIEDs (67.1% [95% CI: 62.1%-72.5%] vs 73.6% [95% CI: 68.9%-78.6%]; P = 0.176). CIED presence showed a nonsignificant association with more adverse outcomes (HR: 1.31; 95% CI: 0.99-1.74; P = 0.063) but was not associated with residual TR >2+ (OR: 0.98; 95% CI: 0.70-1.38; P = 0.915). Achieving residual TR ≤2+ conferred significantly better survival irrespective of CIED presence (P < 0.001). - Conclusions - T-TEER is safe and effective in selected patients with transvalvular CIED leads. Effective TR reduction remains prognostically relevant, even in this high-risk real-world population. |
|---|---|
| Beschreibung: | Online verfügbar: 25. Oktober 2025, Artikelversion: 8. Dezember 2025 Gesehen am 20.02.2026 |
| Beschreibung: | Online Resource |
| ISSN: | 1876-7605 |
| DOI: | 10.1016/j.jcin.2025.09.033 |